To maximize the benefits and minimize potential risks, patient selection for SGLT2 inhibitor therapy should consider several factors: Patients with established cardiovascular disease, heart failure, or chronic kidney disease, especially those with albuminuria, stand to gain substantial benefits from SGLT2 inhibitors [2]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.